small fontsmall fontsmall fontChange Font Size
Print this pagePrint
Create PDFCreate PDF

Welcome to Prevenar13.eu

 

The European Commission has granted Pfizer Inc a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]).

 

Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age.

 

Read the full press release

 

 

If you are a journalist please click here to register to pfizer.eu

 

If you are a US health care professional please visit our website for more information.

 

 

*Prevenar 13 is a registered trade mark of Pfizer